Breadcrumb
MUHC patients are the first enrolled in a new global Phase 1 clinical trial testing Actinium-225, a therapeutic agent used in nuclear precision medicine
Scientist, RI-MUHC, 5252 de Maisonneuve site
...
Tuesdays, 4 p.m. to 5 p.m.
Monthly seminars, 12 to 1 p.m.
Thursdays, 4 p.m. to 5 p.m.
Our EDI PartnersMUHC Board of Directors’ Committee for Action on Inclusion, Diversity and Equity (C-AIDE)The RI-MUHC is a proud Employer...
Equity, Diversity and Inclusion (EDI) in the BRaIN ProgramThe BRaIN Program is committed to supporting and strengthening EDI within the...
Profiles, EDI Advisory CommitteeDiego Herrera, Chair (he/him)Diego Herrera, PhD, is the Equity, Diversity and Inclusion (EDI) Specialist at...